| answer text |
<p>The National Institute for Health and Care Excellence (NICE) published technology
appraisal guidance on the use of lumacaftor-ivacaftor (Orkambi) for the treatment
of cystic fibrosis in July 2016. NICE plans to review its guidance to determine whether
it should be updated in the light of any new evidence in 2019.</p><p> </p><p>If significant
new evidence comes to light before the scheduled review date, NICE has processes in
place to bring forward a review. NICE remains open to a further approach from the
company, with new evidence or a revised price. Although there has been recent correspondence
between NHS England and the company, NICE has not yet received any fresh proposals
from the company.</p>
|
 |
